BR112014023570B1 - Método de purificação da protéina cistationina betasintase (cbs) - Google Patents

Método de purificação da protéina cistationina betasintase (cbs) Download PDF

Info

Publication number
BR112014023570B1
BR112014023570B1 BR112014023570-8A BR112014023570A BR112014023570B1 BR 112014023570 B1 BR112014023570 B1 BR 112014023570B1 BR 112014023570 A BR112014023570 A BR 112014023570A BR 112014023570 B1 BR112014023570 B1 BR 112014023570B1
Authority
BR
Brazil
Prior art keywords
cbs
protein
column
recombinant
imac
Prior art date
Application number
BR112014023570-8A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014023570A2 (pt
Inventor
Richard G. Carrillo
Jan P. Kraus
Tomas Majtan
David Naveh
Original Assignee
The Regents Of The University Of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Colorado filed Critical The Regents Of The University Of Colorado
Publication of BR112014023570A2 publication Critical patent/BR112014023570A2/pt
Publication of BR112014023570B1 publication Critical patent/BR112014023570B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3823—Affinity chromatography of other types, e.g. avidin, streptavidin or biotin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112014023570-8A 2012-03-26 2013-03-25 Método de purificação da protéina cistationina betasintase (cbs) BR112014023570B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261615629P 2012-03-26 2012-03-26
US61/615,629 2012-03-26
US13/830,494 US9243239B2 (en) 2012-03-26 2013-03-14 Purification of cystathionine beta-synthase
US13/830,494 2013-03-14
PCT/US2013/033716 WO2013148580A1 (en) 2012-03-26 2013-03-25 Purification of cystathionine beta-synthase

Publications (2)

Publication Number Publication Date
BR112014023570A2 BR112014023570A2 (pt) 2021-06-01
BR112014023570B1 true BR112014023570B1 (pt) 2022-03-15

Family

ID=49212017

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023570-8A BR112014023570B1 (pt) 2012-03-26 2013-03-25 Método de purificação da protéina cistationina betasintase (cbs)

Country Status (11)

Country Link
US (4) US9243239B2 (enExample)
EP (3) EP3569706A1 (enExample)
JP (3) JP6146934B2 (enExample)
CN (1) CN104540940B (enExample)
AU (1) AU2013240003B2 (enExample)
BR (1) BR112014023570B1 (enExample)
CA (1) CA2867719C (enExample)
HK (1) HK1246350B (enExample)
IL (2) IL234635B (enExample)
IN (1) IN2014DN07920A (enExample)
WO (1) WO2013148580A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) * 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
AU2016354030B2 (en) * 2015-11-09 2022-09-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
MX2019012347A (es) 2017-04-17 2020-01-15 Univ Colorado Regents Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.
WO2020264061A1 (en) * 2019-06-25 2020-12-30 Zymergen Inc. Engineered biosynthetic pathways for production of cystathionine by fermentation
CN114786712A (zh) 2019-06-26 2022-07-22 特拉维尔治疗瑞士有限公司 用于治疗高胱氨酸尿症的酶疗法的PEG化胱硫醚β合成酶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
WO2003106971A2 (en) 2002-06-17 2003-12-24 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE β-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CN1552905A (zh) * 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
WO2011097381A2 (en) 2010-02-04 2011-08-11 The Board Of Regents Of Use University Of Texas System Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase

Also Published As

Publication number Publication date
JP6839595B2 (ja) 2021-03-10
JP2020000259A (ja) 2020-01-09
JP6146934B2 (ja) 2017-06-21
CA2867719A1 (en) 2013-10-03
EP2831229B1 (en) 2017-10-18
CA2867719C (en) 2020-08-11
EP2831229B8 (en) 2018-10-17
EP2831229A1 (en) 2015-02-04
IN2014DN07920A (enExample) 2015-05-01
US10941392B2 (en) 2021-03-09
EP3263701B1 (en) 2019-06-19
JP2015512639A (ja) 2015-04-30
US10160962B2 (en) 2018-12-25
EP3569706A1 (en) 2019-11-20
HK1246350B (en) 2020-05-15
WO2013148580A1 (en) 2013-10-03
US20160177287A1 (en) 2016-06-23
JP2017121255A (ja) 2017-07-13
EP3263701A1 (en) 2018-01-03
IL234635B (en) 2018-12-31
IL263162B (en) 2019-11-28
US20130251700A1 (en) 2013-09-26
BR112014023570A2 (pt) 2021-06-01
CN104540940A (zh) 2015-04-22
CN104540940B (zh) 2018-03-06
AU2013240003A1 (en) 2014-10-02
AU2013240003B2 (en) 2018-04-19
IL263162A (en) 2018-12-31
US20200131497A1 (en) 2020-04-30
JP6952361B2 (ja) 2021-10-20
US9243239B2 (en) 2016-01-26
US20190055537A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
US10941392B2 (en) Purification of cystathionine beta-synthase
Garrow Purification, kinetic properties, and cDNA cloning of mammalian betaine-homocysteine methyltransferase
Kim The methionine sulfoxide reduction system: selenium utilization and methionine sulfoxide reductase enzymes and their functions
US10624959B2 (en) Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
HK1246350A1 (en) Purification of cystathionine beta-synthase
US10280415B2 (en) Human cystathionine β-synthase variants and methods of production thereof
Pollegioni et al. Human D-aspartate oxidase: A key player in D-aspartate metabolism
Chang et al. Serine hydroxymethyltransferase isoforms are differentially inhibited by leucovorin: characterization and comparison of recombinant zebrafish serine hydroxymethyltransferases
HK40016298A (en) Purification of cystathionine beta-synthase
AU2022279663A1 (en) Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine
Yamada et al. Biochemical Characterization of Human Methylenetetrahydrofolate Reductase and Its Common Variants

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/03/2013, OBSERVADAS AS CONDICOES LEGAIS.